What are the pros and cons of launching Oxyglobin immediately? • Pros o Near-term benefits o Generate their first revenues ever (revenues they could use to launch Hemopure) o Value in learning how to “go to market,” making mistakes now rather than with Hemopure o Growing desire to take the company public Proven success would have a greater impact However, could be a con with the recent product failures in the Massachusetts biotechnology community • Cons o Create an unrealistic price expectation for Hemopure if released first because the two products were almost identical o Hospitals and insurance firms will be all over them to justify 500% price difference for what they see as the same product (risk they don’t need) What are the likely competitive environments in the “animal” and “human” blood substitute markets? • Animal: o Biopure is the only company that is actively engaged in the development of a blood substitute for the small-animal veterinary market Baxter or Northfield could attempt to enter the market, but any company wishing to do so
This is the end of the preview. Sign up
access the rest of the document.
This note was uploaded on 09/08/2011 for the course MAR 3023h taught by Professor Kim,j during the Spring '08 term at University of Central Florida.